Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.828,45
-0,38%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aclaris Therapeutics Inc (ACRS) Aclaris Therapeutics Inc (ACRS) Notizie

ACRS

Aclaris Therapeutics (ACRS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACRS
DataOraFonteTitoloSimboloCompagnia
07/05/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422:01GlobeNewswire Inc.Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
30/04/202413:00GlobeNewswire Inc.Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
23/04/202414:00PR Newswire (US)Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive OfficerNASDAQ:ACRSAclaris Therapeutics Inc
05/03/202423:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
27/02/202413:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ACRSAclaris Therapeutics Inc
27/02/202413:00GlobeNewswire Inc.Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
15/02/202402:32Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
05/02/202422:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
16/01/202413:00GlobeNewswire Inc.Aclaris Therapeutics Announces Leadership Changes and Strategic Business ReviewNASDAQ:ACRSAclaris Therapeutics Inc
10/01/202413:00GlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic DermatitisNASDAQ:ACRSAclaris Therapeutics Inc
19/12/202322:01GlobeNewswire Inc.Aclaris Therapeutics Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
05/12/202322:01GlobeNewswire Inc.Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for AlopeciaNASDAQ:ACRSAclaris Therapeutics Inc
13/11/202313:00GlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
06/11/202313:00GlobeNewswire Inc.Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
23/10/202322:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
03/10/202313:00GlobeNewswire Inc.Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)NASDAQ:ACRSAclaris Therapeutics Inc
20/09/202313:00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
18/09/202313:00GlobeNewswire Inc.Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 InhibitorNASDAQ:ACRSAclaris Therapeutics Inc
07/08/202313:00GlobeNewswire Inc.Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
22/06/202322:33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ACRSAclaris Therapeutics Inc
20/06/202322:32Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:ACRSAclaris Therapeutics Inc
13/06/202313:01GlobeNewswire Inc.Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)NASDAQ:ACRSAclaris Therapeutics Inc
12/06/202322:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACRSAclaris Therapeutics Inc
02/06/202313:00GlobeNewswire Inc.Aclaris Therapeutics to Participate in Two June Healthcare Investor ConferencesNASDAQ:ACRSAclaris Therapeutics Inc
08/05/202322:06Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ACRSAclaris Therapeutics Inc
08/05/202313:31Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACRSAclaris Therapeutics Inc
08/05/202313:00GlobeNewswire Inc.Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACRS

La tua Cronologia

BOV
BBASS48
BBASS48 Ex:23,72
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network